Age-related macular degeneration - A therapeutic update

Clinical and Refractive Optometry

Volumn 16, Issue 8, 2005, Pages 240-248

  Brown, Michael D ^a,c   Bowling, Ernest L ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b Medical Building ^*

^c UAB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; PHOTOSENSITIZING AGENT; PHOTREX; RANIBIZUMAB; ROSTAPORFIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ARGON PLASMA COAGULATION; BLINDNESS; BLOOD FILTRATION; CLINICAL TRIAL; EYE SURGERY; GENETICS; HUMAN; LIFESTYLE; NUTRITION; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA TRANSLOCATION; REVIEW; RHEOPHERESIS; RISK FACTOR; TRANSPUPILLARY THERMOTHERAPY; VISUAL IMPAIRMENT;

EID: 27144469878     PISSN: 17054850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. AMD Alliance Homepage, www.amdalliance.org (accessed January, 2002).
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmol 1992; 99: 933-943.
3. AMD Alliance Homepage, www.amdalliance.org (accessed January, 2002).
4. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 1988; 128: 700-710.
5. Delcourt C, Cristol JP, Tessier F, Leger CL, et al. Age-related macular degeneration and antioxidant status in the POLA study. Arch Ophthalmol 1999; 117: 1384-1390.
6. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 1995; 62: 1448S-1461S.
7. The Age-Related Eye Disease Research Group: The Age-Related Eye Disease Study (AREDS): Design implications. AREDS Report No. 1. Controlled Clinical Trials 1999; 20: 573-600.
8. The Age-Related Eye Disease Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 2001; 119: 1417-1436.
9. Ibid.
10. Pratt S. Dietary prevention of age-related macular degeneration. J Am Optom Assoc 1999; 70: 39-47.
11. Hammond BR, Wooten BR, Snodderly DM. Preservation of visual sensitivity of older subjects: association with macular pigment density. Invest Ophthalmol Vis Sci 1998; 39: 397-406.
12. Malinow MR, Feeny-Burns L, Peterson LH, et al. Diet-related macular anomalies in monkeys. Invest Ophthalmol Vis Sci 1980; 19: 857-863.
13. Berendschot TT, Goldbohm RA, Klopping WA, et al. Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest Ophthalmol Vis Sci; 41: 3322-3326.
14. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75(4): 216-230.
15. National Eye Institute Homepage: http://www.nei.nih.gov/ news/statements/lutein.asp (accessed June 2005).
16. Heiba EVI, Elston RC, Klein BE, et al. Sibling correlations and segregation analysis of age-related maculopathy: The Beaver Dam Eye Study. Genet Epidemiol 1994; 11: 51-67.
17. Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol 1993; 111: 104-109.
18. Delcourt C, Diaz JL, Ponten-Sanchez A, Papoz L. Smoking and age-related macular degeneration: The POLA Study. Arch Ophthalmol 1998; 116: 1031-1035.
19. The Age-Related Eye Disease Research Group: The Age-Related Eye Disease Study (AREDS): Risk factors associated with age-related macular degeneration. AREDS Report No. 3. Ophthalmology 2000; 107: 2224-2232.
20. Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 2000; 117: 351-358.
21. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol 1998; 116: 583-587.
22. Obisesan TO, Hirsch R, Kosoko O, Carlson L, et al. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J Am Geriatr Soc 1998; 46: 1-7.
23. Eunyoung C, Hankinson SE, Willet WC, Stampfer MJ, et al. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Arch Ophthalmol 2000; 118:681-688.
24. Moss SE, Klein R, Klein BEK, Jenson SC, et al. Alcohol consumption and the 5-year incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1998; 105: 789-794.
25. Cruickshanks KJ, Klein R, Klein BEK, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol 2001; 119: 246-250.
26. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol 1987; 105: 209-213.
27. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinicalv trials. Arch Ophthalmol 1993; 111: 1200-1209.
28. Fine S. Photodynamic therapy with Verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol 1999; 10: 1400-1402.
29. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized trials. TAP Report 1. Arch Opthalmol 1999; 117: 1329-1345.
30. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized trials. TAP Report 2. Arch Ophthalmol 2001; 119: 198-207.
31. Bressler NM. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized trials. TAP Report 2. Letter to the Editor. Am J Ophthalmol 2002; 1: 168-169.
32. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131(5): 541-560.
33. Lewis H. Subfoveal choroidal neovascularizationns there a role for submacular surgery? Editorial. Am J Ophthalmol 1998; 126: 127-129.
34. Bressler NM, Hawkins BS, Steinberg P, McDonald HR. Are the submacular surgery trials (SST) still relevant in an era of photodynamic therapy? Ophthalmology 2001; 108: 435-436.
35. Machemer R. Macular translocation. Editorial. Am J Ophthalmol 1998; 125: 698-700.
36. Heier JS, Sy JR, McClusky ER, rhuFab V2 Study Group. RhuFab V2 in wet AMD-6 month continued improvement following multiple intravitreal injections. ARVO Abstract #972, 2003.
37. Barouch FC, Miller JW Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 2004; 44(3): 23-32.
38. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for the subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmol 2003; 110(5): 979-986.
39. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110(12): 2372-2385.
40. Pulido JS. Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002; 100: 85-107.
41. Bennett SI. Age-related macular degeneration update. Optometric Management 2001; 36: 106-110.
42. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt's disease gene (ABCR) in age-related macular degeneration. Science 1997; 277: 1805-1807.